JP2009508818A5 - - Google Patents

Download PDF

Info

Publication number
JP2009508818A5
JP2009508818A5 JP2008529335A JP2008529335A JP2009508818A5 JP 2009508818 A5 JP2009508818 A5 JP 2009508818A5 JP 2008529335 A JP2008529335 A JP 2008529335A JP 2008529335 A JP2008529335 A JP 2008529335A JP 2009508818 A5 JP2009508818 A5 JP 2009508818A5
Authority
JP
Japan
Prior art keywords
alkyl
group
optionally substituted
substituents
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008529335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508818A (ja
JP5165568B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/034334 external-priority patent/WO2007028082A1/en
Publication of JP2009508818A publication Critical patent/JP2009508818A/ja
Publication of JP2009508818A5 publication Critical patent/JP2009508818A5/ja
Application granted granted Critical
Publication of JP5165568B2 publication Critical patent/JP5165568B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008529335A 2005-09-01 2006-09-01 5−HT2C受容体アゴニストとしての6−置換−2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン Expired - Fee Related JP5165568B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71349505P 2005-09-01 2005-09-01
US60/713,495 2005-09-01
PCT/US2006/034334 WO2007028082A1 (en) 2005-09-01 2006-09-01 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists

Publications (3)

Publication Number Publication Date
JP2009508818A JP2009508818A (ja) 2009-03-05
JP2009508818A5 true JP2009508818A5 (enExample) 2009-10-15
JP5165568B2 JP5165568B2 (ja) 2013-03-21

Family

ID=37499682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008529335A Expired - Fee Related JP5165568B2 (ja) 2005-09-01 2006-09-01 5−HT2C受容体アゴニストとしての6−置換−2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン

Country Status (13)

Country Link
US (1) US7994163B2 (enExample)
EP (1) EP1924560B1 (enExample)
JP (1) JP5165568B2 (enExample)
AT (1) ATE438627T1 (enExample)
CA (1) CA2619566C (enExample)
CY (1) CY1110531T1 (enExample)
DE (1) DE602006008323D1 (enExample)
DK (1) DK1924560T3 (enExample)
ES (1) ES2328520T3 (enExample)
PL (1) PL1924560T3 (enExample)
PT (1) PT1924560E (enExample)
SI (1) SI1924560T1 (enExample)
WO (1) WO2007028082A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028132A2 (en) * 2005-09-01 2007-03-08 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
US8420631B2 (en) * 2005-09-01 2013-04-16 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
EP2942346B1 (en) * 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
AU2011293612B2 (en) 2010-08-23 2015-11-26 Syntrix Biosystems Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
KR20130138768A (ko) * 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 5-ht2c 아고니스트의 신속-용해성 투여 형태
JP2013539470A (ja) * 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ, インコーポレイテッド ロルカセリンと光学活性な酸との塩
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ht2c 아고니스트의 비-흡습성 염
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
AU2021398540A1 (en) 2020-12-11 2023-06-22 Intervet International B.V. Anthelmintic compounds comprising a pyridine structure

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265890A (en) 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
GB9116824D0 (en) * 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
WO1993004866A1 (fr) * 1991-09-11 1993-03-18 Canon Kabushiki Kaisha Element de nettoyage ameliore pour tete de jet d'encre et dispositif a jet d'encre equipe d'un tel element de nettoyage
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5698766A (en) 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP1213017A3 (en) 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
BR0211140A (pt) 2001-07-13 2005-10-25 Upjohn Co Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht
JP2005535560A (ja) * 2001-11-28 2005-11-24 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 治療用の化合物
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
US8367657B2 (en) 2003-06-17 2013-02-05 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005042491A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CA2556390C (en) 2004-02-25 2012-10-02 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
EP2149562A1 (en) 2004-12-21 2010-02-03 Arena Pharmaceuticals, Inc. method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
NZ589951A (en) 2004-12-23 2012-11-30 Arena Pharm Inc 5HT2C receptor modulator compositions and methods of use
US8420631B2 (en) * 2005-09-01 2013-04-16 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists

Similar Documents

Publication Publication Date Title
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
JP2008531574A5 (enExample)
JP2014507464A5 (enExample)
JP2009534386A5 (enExample)
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
JP2013544276A5 (enExample)
JP2010031025A5 (enExample)
JP2007517807A5 (enExample)
JP2010502751A5 (enExample)
JP2013505969A5 (enExample)
JP2009519243A5 (enExample)
JP2012041349A5 (enExample)
RU2011129383A (ru) Производное амина, обладающее антагостической активностью в отношении рецептора npy y5
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
JP2011504903A5 (enExample)
JP2009523777A5 (enExample)
JP2013514367A5 (enExample)
JP2009507034A5 (enExample)
JP2010501478A5 (enExample)
JP2005518357A5 (enExample)
WO2008126901A1 (ja) 含窒素複素環化合物およびそれを含有する医薬組成物
JP2013544854A5 (enExample)
JP2013540712A5 (enExample)
JP2009541240A5 (enExample)